Vabysmo crosses $4B mark, Polivy joins blockbuster club as Roche preps for key readouts

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. Still, questions continue to swirl about an evolving market showdown with Regeneron’s rival drug.